Skip to main content
Displaying 421 - 432 of 452
Display:
12
24
48
Metabolism, Alcohol & Toxicity
4
Intercept: Emerging trends in the care pathway for patients with NASH - Digital ILC 2020
View
General Hepatology
6
Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020
View
General Hepatology
6
Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020
View
General Hepatology
6
Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020
View
General Hepatology
6
Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020
View
General Hepatology
6
Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020
View
General Hepatology
6
Intercept: FXR agonism in clinical practice: new perspectives from the real-world experience in PBC - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Viral Hepatitis
5
Gilead: A NEW VIRUS IN THE MIX: Re-imagining liver disease care in the COVID-19 era - Digital ILC 2020
View
Pagination
First page
« First
Previous page
‹ previous
…
Page
30
Page
31
Page
32
Page
33
Page
34
Page
35
Current page
36
Page
37
Page
38
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy